In both cases, the effective protection of human subjects should receive much higher priority, thereby justifying the modest added expense, which probably would amount to no more than 1-2% of the overall cost of clinical studies.
En ambos casos, debe darse prioridad a la protección efectiva de los humanos sujetos a experimentos, con lo que se justificaría el modesto aumento de los gastos, que probablemente no sería superior al 1 o 2% de los costos totales de los estudios clínicos.